Skip to content

Timing Evaluation of Stoma Closure (TIMES). Early vs Late Closure of Stoma After Rectal Cancer Surgery.

Timing Evaluation of Stoma Closure (TIMES). Early vs Late Closure of Stoma After Rectal Cancer Surgery.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05284864
Acronym
TIMES
Enrollment
150
Registered
2022-03-17
Start date
2022-01-01
Completion date
2024-12-01
Last updated
2022-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ileostomy Closure, Ileostomy; Complications, Ileostomy - Stoma, Rectal Cancer, Total Mesorectal Excision

Brief summary

The purpose of this study is to asses the safety and efficacy of early stoma closure (2-3 weeks after total mesorectal excision) vs late closure (16-24 weeks after mesorectal excision).

Detailed description

Total mesorectal excision (TME) is considered the gold standard in obtaining a negative circumferential resection margin for cancers of the middle and lower third of the rectum. Despite all the oncological benefits,TME in ultra-low anterior resection carries some important drawbacks, such as a longer operative time, and its association with a higher rate of anastomotic leakage which increases in the most distal anastomoses. Among the measures adopted to reduce mortality, the creation of protective ostomies has proven to be effective, however the protective ileostomy and its closure are not free of complications, such as dehydration and chronic kidney failure. In the investigator's country, various studies have analyzed this time to closure, being 10.8 months on average and with an increase in morbidity when closure is delayed the longest. There are few prospective studies on the timing of stoma closure, which mainly focused on morbidity and mortality related to early closure. These studies did not demonstrate any significant negative effects on morbidity or mortality. The reason for early closure of the stoma is to reduce complications related to it. Although its true incidence is unknown, most patients have some type of stoma-related complication, which can be avoided or decreased in the case of early closure. In addition to the complications on the patient and their quality of life, the hospital costs secondary to them are not negligible. The TIMES study (TIMing Evaluation of Stoma closure) arises from the need to know the ideal moment for the closure of derivative stomata after rectal surgery. Therefore, the hypothesis is that patients who undergo early ileostomy closure (at 2-3 weeks) after ultra-low anterior resection have fewer complications than patients with late ileostomy closure (4-6 months). The main objective of this study is to analyze the morbidity and mortality associated with both early (early group, CASES group) and late closure (late group, CONTROL group) of the derivative ileosomy. In this study, patients scheduled for temporary stoma closure after scheduled colorectal surgery will be randomized into two groups: early closure (14-21 days after surgery) or late closure (4th-6th month after surgery). Patients will be followed from the time of study entry until 12 months after stoma closure.

Interventions

PROCEDUREStoma closure

Stoma closure after rectal surgery

Sponsors

Hospital Universitario La Fe
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with rectal cancer (with / without metastasis) (with / without chemoterapy or radiotherapy) * Patients undergoing low or ultra low anterior resection with anastomosis and stoma of protection. * Patients with no intraoperative or postoperative complications. * Radiological confirmation of the absence of anastomotic compilations (opaque enema or abdominal-pelvic CT scan with rectal contrast) * Confirmation by rectoscopy of the absence of anastomotic compilations

Exclusion criteria

* Rectal cancer surgeries without anastomosis. * Rectal cancer surgeries without stoma of protection.

Design outcomes

Primary

MeasureTime frame
Determine and compare morbidity and mortality rates in patients with early and late stoma closureFrom rectal surgery to stoma closure surgery

Secondary

MeasureTime frameDescription
Determine and analyze quality of life assisted by the SF36 scale in early vs late ileostomy closure1 month, 6 month and 1 year after stoma closure surgeryThe SF36 is a short questionnaire with 36 items which measure eight multi-item variables: physical functioning (10 items), social functioning (two items), role limitations due to physical problems (four items), role limitations due to emotional problems (three items), mental health (five items), energy and vitality (four items), pain (two items), and general perception of health (five items). There is a further unscaled single item on changes in respondents' health over the past year. For each variable item scores are coded, summed, and transformed on to a scale from 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state).

Other

MeasureTime frameDescription
Determine the patient's percentage with anterior resection syndrome, after early and late ileostomy closure assisted by the LARS scale.1 month, 6 month and 1 year after stoma closure surgeryThe LARS score has been validated and translated into several languages. By applying binomial regression on patient responses, the five issues that most bothered the patients were selected: incontinence for flatus, incontinence for liquid stool, frequency, clustering and urgency. Rating scale ranges from 0 to 42 points, and patients are classified into three groups: no LARS (0-20 points), minor LARS (21-29 points) and major LARS (30-42 points). According to the authors, the LARS score facilitates a fast identification of patients categorized as major LARS who will require treatment

Countries

Spain

Contacts

Primary ContactDavid Abelló
davidabello1@gmail.com+34630306333

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026